Ongoing Clinical Trials Actively Recruiting Patients With Bladder Cancer


Get Permission

The information in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with bladder cancer. The list includes randomized and nonrandomized phase 0 to III studies as well as observational clinical trials evaluating new therapies, surgical techniques, and devices; image-guided radiation and radiation doses; noninvasive assays to detect bladder cancer cells; molecular profiling; and quality of life. All of the studies are listed on the National Institutes of Health website at ClinicalTrials.gov.

Bladder Cancer

Study Type: Phase 0/interventional/randomized

Study Title: An Immunopharmacodynamic Phase 0/I Study of Rapamycin in Patients Undergoing Radical Cystectomy for Bladder Cancer

Study Sponsor and Collaborators: The University of Texas Health Science Center at San Antonio

Purpose: To evaluate the effects of rapamycin directly on bladder tumors and the effects of rapamycin on the immune system of patients with bladder cancer

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Tissue pharmacodynamic response to TORC1 inhibition (time frame: 30 days)

Principal Investigator: Robert S. Svatek, MD, MSCI, UT Health Science Center San Antonio; 210-567-5676

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01827618



Study Type
: Phase 0/interventional/single-group assignment

Study Title: Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer

Study Sponsor and Collaborators: State University of New York-Upstate Medical University

Purpose: To test whether the drug valproic acid can cause changes in bladder tumors that might inhibit their growth

Ages Eligible for Study: 21 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Thrombospondin-1 gene expression (time frame: 1 day)

Principal Investigator: Oleg Shapiro, MD, State University of New York-Upstate Medical University. Contact: Barbara McConnell; 315-464-4473; mcconneb@upstate.edu

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01738815



Study Type
: Phase 0/interventional/single-group assignment

Study Title: Noninvasive Vibrational Device to Improve Sensitivity of Urine Cytology for Bladder Cancer

Study Sponsor and Collaborators: Johns Hopkins University

Purpose: To test whether a commercially available vibrating chair can increase the number of urothelial cells in a urine sample of healthy participants noninvasively.

Ages Eligible for Study: 18 to 80 years

Genders Eligible for Study: Male

Accepts Health Volunteers: No

Primary Outcome Measures: Number of cancer cells (time frame: up to 24 weeks)

Principal Investigator: Trinity Bivalacqua, MD, PhD, Johns Hopkins University. Contact: John J. Kim, BS; 805-220-8765; jkim324@jhu.edu

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01826097



Study Type
: Interventional/nonrandomized/single-group assignment

Study Title: Pilot Pre-cystectomy Trial of Broccoli Extract in Patients With Superficial or Locally Advanced Bladder Cancer

Study Sponsor and Collaborators: Roswell Park Cancer Institute; Johns Hopkins University

Purpose: To study the side effects of broccoli sprout extract in treating patients with transitional cell bladder cancer undergoing surgery

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Toxicity as assessed by National Cancer Institute Common Toxicity Criteria version 3.0 (time frame: 14 days)

Principal Investigator: Roberto Pili, MD, Roswell Park Cancer Institute. Contact: AskRPCI, MD 877-275-7724; askrpci@roswellpark.org

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01108003



Study Type
: Phase I/interventional/nonrandomized

Study Title: Phase I Dose-Escalation Study of Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy

Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center

Purpose: To test the safety of different doses of external-beam radiation therapy combined with chemotherapy

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: To determine the dose limiting toxicity and establish the maximal tolerated dose (time frame: 2 years)

Principal Investigator: Marisa Kollmeier, MD, Memorial Sloan Kettering Cancer Center; 212-639-3952

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01104350



Study Type
: Phase I/II/interventional/single-group assignment

Study Title: A Phase I-II Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Bladder Cancer

Study Sponsor and Collaborators: University of Washington; National Cancer Institute

Purpose: To investigate the side effects and the best dose of sirolimus when given together with cisplatin and gemcitabine hydrochloride and how well it works in treating patients with bladder cancer

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Maximum tolerated dose of sirolimus based on the incidence of dose-limiting toxicity graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events version 4.0 (phase 1) (time frame: up to 28 days)

Principal Investigator: Robert B. Montgomery, MD, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; 206-616-8289

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01938573



Study Type: Phase II/interventional/randomized

Study Title: A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7 in Older Subjects Following Chemotherapy

Study Sponsor and Collaborators: National Cancer Institute

Purpose: To study the effects of IL-7 on immune system function in two different groups of older people. One group will be people who have completed chemotherapy treatment for breast, colon, or bladder cancer. The other group will be people who have never received chemotherapy.

Ages Eligible for Study: 60 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: Yes

Primary Outcome Measures: Vaccines responses (time frame: up to 1 year); quality of immune responses (time frame: 8 weeks); safety of rhIL-7 (time frame: up to 1 year)

Principal Investigator: Ronald E. Gress, MD, National Cancer Institute; 301-496-1791; gressr@mail.nih.gov

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01339000



Study Type
: Phase II/interventional/nonrandomized

Study Title: A Multi-Histology Phase II Study of 5-Fluoro-2’-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)

Study Sponsor and Collaborators: National Cancer Institute

Purpose: To determine the effectiveness, safety, and tolerability of FdCyd and THU when given together to control tumor growth in patients with bladder cancer, non–small cell lung cancer, breast cancer, or head or neck cancer that has progressed after receiving standard treatment or for which no effective therapy exists

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Determine progression-free survival and/or the response rate (complete plus parital responses) of FdCyd administered 5 days/week for 2 weeks, in 28-day cycles, by intravenous infusion with THU in patients with breast cancer, head and neck cancer, non–small cell lung cancer, and bladder cancer.

Principal Investigator: James H. Doroshow, MD, National Cancer Institute; 301-496-4291; doroshoj@mail.nih.gov

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT00978250



Study Type
: Phase II/interventional/single-group assignment

Study Title: Phase II Study of Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center; University of North Carolina, Chapel Hill; New York University

Purpose: To determine if standard chemotherapy (gemcitabine and cisplatin) given on a dose-dense treatment schedule (with less time between treatments) can help shrink the tumor better than standard chemotherapy given on a standard treatment schedule before the patient undergoes surgery for bladder cancer

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Pathologic response rate (time frame: 1 year)

Principal Investigator: Dean Bajorin, MD, Memorial Sloan Kettering Cancer Center; 646-422-4333

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01589094



Study Type
: Phase II/interventional/single-group assignment

Study Title: Phase II Study of Adjuvant Conformal Radiotherapy in High Risk Bladder Cancer

Study Sponsor and Collaborators: Emory University

Purpose: To study how well modern, conformal radiation therapy after surgery works in treating patients with high-risk bladder cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Gastrointestinal late effects, assessed using Radiation Therapy Oncology Group Late Effects in Normal Tissues Subjective, Objective, Management and Analytic Scales (time frame: 3 months)

Principal Investigator: Joseph W. Shelton, MD, Emory University; 404-616-6343; jwshelt@emory.edu

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01954173



Study Type
: Phase II/interventional/single-group assignment

Study Title: A Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Restaging

Study Sponsor and Collaborators: Radiation Therapy Oncology Group; National Cancer Institute; NRG Oncology Foundation, Inc

Purpose: To study how well radiation therapy given together with chemotherapy works in treating patients with stage I bladder cancer

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Rate of freedom from radical cystectomy at 3 years (time frame: 3 years from date of registration)

Principal Investigator: William U. Shipley, MD, FACR, Massachusetts General Hospital. See individual clinical trial locations for contact ­information.

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT00981656



Study Type
: Phase III/interventional/randomized

Study Title: A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer

Study Sponsor and Collaborators: Southwest Oncology Group; National Cancer Institute

Purpose: To study standard pelvic lymphadenectomy to see how well it works compared to extended pelvic lymphadenectomy in treating patients undergoing surgery for invasive bladder cancer

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Disease-free progression

Principal Investigator: Seth P. Lerner, MD, Baylor College of Medicine; 713-798-6841

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01224665



Study Type
: Observational/patient registry

Study Title: Pilot Study of Role of MRI in Neoadjuvant Chemotherapy for Bladder Cancer

Study Sponsor and Collaborators: New York University School of Medicine

Purpose: This is a prospective study of pretreatment DW-MRI to identify potential imaging biomarkers predictive of response to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Complete pathologic response (time frame: < 1 year)

Principal Investigator: Arjun Balar, MD, NYU Langone Medical Center. Contact: Simone Rainey; 212-263-2710; simone.rainey@nyumc.org

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01922232



Study Type
: Observational

Study Title: PORCH: A Registry of Prospective Outcomes of Radical Cystectomy With or Without Chemotherapy

Study Sponsor and Collaborators: UNC Lineberger Comprehensive Cancer Center

Purpose: To create a registry of older patients undergoing surgical and/or medical treatment for bladder cancer. The registry will record side effects and outcomes related to the treatment using different surveys and biological measures.

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: To collect the number of changes in functional status, surgical complications, and survival status collected in a prospective database of patients undergoing a radical cystectomy with or without chemotherapy (time frame: 1 year)

Principal Investigator: Angela Smith, MD, University of North Carolina Lineberger Comprehensive Cancer Center

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT01776138



Study Type
: Observational

Study Title: A Prospective Study of Quality of Life in Patients With Bladder Cancer

Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center; Albert Einstein College of Medicine of Yeshiva University; North Shore Long Island Jewish Health System

Purpose: To learn about the quality of life of people living with bladder cancer. The researchers are interested in learning how treatments for bladder cancer affect people. Their findings could help provide better care and information to patients with bladder cancer.

Ages Eligible for Study: 18 years and older

Genders Eligible for Study: Both

Accepts Health Volunteers: No

Primary Outcome Measures: Prospectively characterize the impact of radical cystectomy and different urinary diversions on quality of life of patients with bladder cancer

Principal Investigator: Bernard Bochner, MD, Memorial Sloan Kettering Cancer Center; 646-422-4387

For More Information: Visit ClinicalTrials.gov and refer to this study by its identifier: NCT00745355



Advertisement

Advertisement



Advertisement